TheraRadar
Landscape → Oncology

Mesothelioma Clinical Trial Landscape

Data updated: May 20, 2026

275 clinical trials tracked since 2008

Mesothelioma is being studied across 275 clinical trials registered since 2008, with 91 programs currently active. The competitive pipeline includes 1 active Phase 3 trials, 54 active Phase 2 trials, and 59 active Phase 1 trials. Top industry sponsors include Novartis, AstraZeneca, Seagen, a wholly owned subsidiary of Pfizer.

91 active
/
275 total (since 2008)
59
Phase 1 Active
156 total
54
Phase 2 Active
158 total
1
Phase 3 Active
17 total
0
Phase 4 Active
3 total

Top Industry Sponsors

Sorted by active Active Done Failed
Novartis 3 0 0
AstraZeneca 2 1 0
Seagen, a wholly owned subsidiary of Pfizer 2 0 0
TCR2 Therapeutics 2 0 0
NGM Biopharmaceuticals, Inc 2 0 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT06097728 RECRUITING
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
AstraZeneca n=825
NCT03710876 COMPLETED
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
Ferring Ventures Limited n=53
NCT04334759 COMPLETED
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
PrECOG, LLC. n=214
NCT03762018 COMPLETED
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
ETOP IBCSG Partners Foundation n=400
NCT03063450 COMPLETED
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma
University of Southampton n=332

+ 12 more Phase 3 trials — see full database below

Mesothelioma — Trials Started by Year (last 10 years)

2016
21
2017
18
2018
18
2019
25
2020
14
2021
21
2022
19
2023
17
2024
22
2025
11
2026
8

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Novartis
3
AstraZeneca
3
Seagen, a wholly owned subsidiary of Pfizer
2
TCR2 Therapeutics
2
NGM Biopharmaceuticals, Inc
2
Bristol-Myers Squibb
3
Merck
2
Verismo Therapeutics
1
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
1
Orion Corporation, Orion Pharma
1

Active Trials by Phase

Phase 1
59
Phase 2
54
Phase 3
1

Enrollment Size Distribution

1-50
140
51-200
89
201-500
26
501-1k
6
1k+
1

All Industry Sponsors

Sorted by active Active Done Failed
Novartis 3 0 0
AstraZeneca 2 1 0
Seagen, a wholly owned subsidiary of Pfizer 2 0 0
TCR2 Therapeutics 2 0 0
NGM Biopharmaceuticals, Inc 2 0 0
Bristol-Myers Squibb 1 2 0
Merck 1 1 0
Verismo Therapeutics 1 0 0
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany 1 0 0
Orion Corporation, Orion Pharma 1 0 0
Perspective Therapeutics 1 0 0
7 Hills Pharma, LLC 1 0 0
KaliVir Immunotherapeutics 1 0 0
Genmab 1 0 0
IDEAYA Biosciences 1 0 0
NCT06097728 RECRUITING
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
AstraZeneca n=825
NCT04158141 TERMINATED
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NRG Oncology n=16
NCT03710876 COMPLETED
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
Ferring Ventures Limited n=53
NCT04334759 COMPLETED
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
PrECOG, LLC. n=214
NCT03762018 COMPLETED
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
ETOP IBCSG Partners Foundation n=400
NCT03063450 COMPLETED
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma
University of Southampton n=332
NCT02349412 COMPLETED
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology n=405
NCT02784171 COMPLETED
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Canadian Cancer Trials Group n=520
NCT02899299 COMPLETED
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Bristol-Myers Squibb n=605
NCT03610360 COMPLETED
DENdritic Cell Immunotherapy for Mesothelioma
Amphera BV n=176
NCT02709512 COMPLETED
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Polaris Group n=249
NCT00651456 COMPLETED
Mesothelioma Avastin Plus Pemetrexed-cisplatin Study
Intergroupe Francophone de Cancerologie Thoracique n=448
NCT02991482 COMPLETED
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma
ETOP IBCSG Partners Foundation n=144
NCT01098266 COMPLETED
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
AGC Biologics S.p.A. n=400
NCT01907100 TERMINATED
Nintedanib (BIBF 1120) in Mesothelioma
Boehringer Ingelheim n=545
NCT01604005 TERMINATED
PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma
Brynn Chappell n=375
NCT02511600 WITHDRAWN
Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication
M.D. Anderson Cancer Center

Full Mesothelioma Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only